| abstract |
The disclosure relates to a form 1 and form 2 polymorph of (-)-trans -3 -(5,6- dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine-2,5-dione. The present disclosure also relates to (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4- (1H-indol-3-yl) pyrrolidine-2, 5-dione compounds having a chiral purity greater than 99%, and methods of preparation of these compounds. Also disclosed are pharmaceutical compositions comprising these (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione compounds, which are suitable for treating a cell proliferative disorder, such as a cancer. |